Nov 15, 2017

Summary

Notable Earnings update: YRD

90:

• IPO: AQ
• Others: NKTR

---

Earnings update

YRD – Yirendai Ltd
-Yirendai Ltd. engages in the online consumer finance business. The Company provides services for both online and offline marketplace connecting borrowers and investors, as well as wealth management services. Yirendai serves customers in China.

Classification: Informed Spec

Earnings review/Update:

 

– Earnings beat
– In 3Q, Yirendai facilitated RMB 12,185.4 million (US$1,831.5 million) of loans to 192,725 qualified individual borrowers through its online marketplace, representing a year-over-year growth of 117%; 75.7% of the borrowers were acquired from online channels; 57.2% of the loan volume was originated from online channels and nearly 100% of the online volume was facilitated through mobile.
– Both investors and borrowers grew in 3Q
– 11% of borrowers were repeat borrowers from top-up loans in 3Q from 5% in 2Q

90 degree stock

AQ – Aquantia Corp.
– Aquantia Corp. develops communications integrated circuits and semiconductor devices. The Company offers products for ethernet connectivity in the data center, access, and enterprise infrastructure markets. Aquantia serves clients worldwide.

Classification: Informed Spec

News:
-IPO Price: 9
– Market cap: 380Mil

NKTR – Nektar Therapeutics
-Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company’s product pipeline is comprised of early to late stage drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral, and immunology.

Classification: Informed Spec

News:
-Combination of Opdivo and Nektar’s NKTR-214 show positive effect in advanced lung cancer in Phase 1/2 study.